Evidence map›Paper›PMID 41843147›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026

Evaluation of ATP12A and NFKBIZ as potential markers of inflammatory status in cystic fibrosis airway epithelial cells.

Caterina Allegretta, Daniela Guidone, Silvia Boscia, Laura Pisano, Silvia Ricci, Chiara Azzari, Cristina Fevola, Martina De Santis, Fabiana Ciciriello, Enza Montemitro and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Caterina Allegretta *Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Daniela Guidone *Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
Silvia BosciaImmunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Laura PisanoImmunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Silvia RicciImmunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Chiara AzzariImmunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Cristina FevolaDepartment of Pediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital IRCCS, Florence, Italy.
Martina De SantisTelethon Institute of Genetics and Medicine, Pozzuoli, Italy.
Fabiana CicirielloCystic Fibrosis Center, Specialistic Pediatrics Department, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
Enza MontemitroCystic Fibrosis Center, Specialistic Pediatrics Department, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
Daniela DolceDepartment of Pediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital IRCCS, Florence, Italy.
Giulio CabriniDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Luis J V GaliettaTelethon Institute of Genetics and Medicine, Pozzuoli, Italy.
Vito TerlizziDepartment of Pediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital IRCCS, Florence, Italy.
Onofrio LaselvaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy. onofrio.laselva@unifg.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople with Cystic Fibrosis (pwCF) are prone to bacterial lung infections with P. aeruginosa, which have been linked to chronic inflammation in the lung. Although the highly effective CFTR modulator therapy (Elexacaftor-Tezacaftor-Ivacaftor, ETI) has dramatically improved respiratory outcomes in pwCF, airway inflammation and bacterial colonization persist in the upper and lower respiratory tracts.

methodsWe investigated the effect of ETI in both plasma and fresh primary nasal epithelial (HNE) cells obtained from pwCF pre- and post-three months of ETI treatment. Given that inflammation has been shown to upregulate NFKBIZ and the ATP12A proton pump, we measured their levels in fresh HNE cells and in cultured HNE cells exposed to clinical exoproducts (EXO) of P. aeruginosa or other inflammatory stimuli.

resultsELISA analysis revealed a significant reduction of IL-6, IL-8, and IL-17C in both plasma and HNE cells after ETI treatment. NFKBIZ and ATP12A expression was increased after infection and inflammatory stimuli in CF bronchial epithelial (CFBE) and HNE cells, and this increase was reduced by Dimethyl-Fumarate, an anti-inflammatory drug.

conclusionsThese preclinical studies, using patient-derived tissues, suggest that NFKBIZ and ATP12A may play a relevant role in the pathophysiology and inflammatory response of the CF airway epithelium.

Indexed as

Cystic FibrosisEpithelial CellsAminophenolsBenzodioxolesBiomarkersCells, CulturedCytokinesH(+)-K(+)-Exchanging ATPaseHumansIndolesInflammationPseudomonas aeruginosaQuinolonesThiophenesAminophenolsATP12A protein, humanBenzodioxolesBiomarkersCytokinesH(+)-K(+)-Exchanging ATPaseIndolesQuinolonestezacaftorThiophenesATP12ACystic FibrosisInfectionInflammationNFKBIZ

Identifiers

PMID41843147
PMCPMC12995941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.